The EasyBoost trial evaluates EA-230 as a potential new treatment option to improve recovery following major cardiac surgery, building on Phase II results in which patients treated with EA-230 had a two-day shorter median hospital stay (8 versus 10 days; p=0.001)
THE HAGUE, the Netherlands, Nov. 19, 2026 (GLOBE NEWSWIRE) -- EBI NL B.V. (EBI NL), a Dutch Group company of Exponential Biotherapies, Inc. (EBI), today announced that the first patient has been enrolled in the EasyBoost trial (NCT07357675), a multicentre, multinational, randomised, double-blind, placebo-controlled Phase III clinical trial evaluating its proprietary investigational compound EA-230 in patients undergoing elective on-pump coronary artery bypass grafting (CABG) surgery. The trial aims to enrol approximately 300 patients, randomised 1:1 to EA-230 or placebo, at leading cardiac surgery centres across the United States, the United Kingdom and the European Union, and is conducted in collaboration with CR2O B.V., a Netherlands-based, full-service Contract Research Organisation.
EA-230, a potential first-in-class medicine derived from the human pregnancy hormone hCG, is designed to improve recovery following major surgery by mitigating the adverse vascular response to surgical stress, to boost and maintaining vascular integrity and haemodynamic stability. Through these effects, EA-230 has the potential to reduce the burden of postoperative complications and to enable patients to recover faster from major surgery and leave the hospital sooner.
New treatment to improve postoperative recovery are urgently needed. CABG is the most common type of open-heart surgery in the United States, yet despite advances in surgical and perioperative care, complications following major surgery remain an important clinical burden for patients, affecting multiple organ systems, delaying recovery and prolonging intensive care unit and hospital stay. Every day saved in hospital matters: to patients and their families, and to health systems facing pressure on beds and budgets.
EA-230 has been evaluated across multiple clinical trials, providing encouraging evidence of its potential to improve recovery following major surgery. In a randomised, double-blind, placebo-controlled Phase II trial in 180 patients undergoing on-pump cardiac surgery, published in Critical Care Medicine, EA-230 was well tolerated, and patients treated with EA-230 had a significantly shorter hospital stay of approximately two days compared with placebo-treated patients (median 8 versus 10 days; p=0.001). Patients receiving EA-230 also had a less positive fluid balance on the first day after surgery (217 mL versus 605 mL; p=0.01), in line with its proposed effect on vascular integrity. A subsequent analysis indicated that treatment with EA-230 was also associated with a shorter duration of postoperative complications that required medical treatment, which EasyBoost will assess prospectively as a secondary endpoint.
Building on these promising results, progression into the Phase III clinical trial marks a major milestone in the development of EA-230. The EasyBoost Phase III trial is designed to confirm findings from earlier clinical development and establish the potential of EA-230 to improve postoperative recovery in patients undergoing CABG surgery. CABG is the first indication for EA-230. EBI sees a significant opportunity for EA-230 across other major surgical procedures where the body’s response to surgical stress drives complications and prolongs recovery.
The primary objective of the EasyBoost trial is to assess the effect of EA-230 on required postoperative hospital length of stay, the time patients need to remain in hospital after surgery before they meet the criteria for discharge. The trial will also evaluate time required in the intensive care unit, the duration of postoperative complications, haemodynamic stability, pharmacokinetics and safety. The trial design has been discussed with the U.S. Food and Drug Administration, and EasyBoost is designed to support regulatory submissions in the United States and Europe.
EBI expects to complete the EasyBoost trial and report topline results around the end of 2027.
“Enrolling the first patient in the EasyBoost trial marks a defining milestone for EBI, for the development of EA-230 and, we hope, for the many patients who face cardiac surgery every year,” said [Niels Bakker, CFO, EBI]. “Earlier clinical development provided encouraging evidence of EA-230’s potential to help patients undergoing cardiac surgery recover faster and go home sooner. We believe EA-230 could become the first medicine approved to shorten recovery after cardiac surgery. EasyBoost is the next important step in confirming the potential of EA-230 to improve recovery following major surgery, in a rigorous, international trial at leading cardiac surgery centres. We are grateful to the patients, investigators and clinical partners whose participation and collaboration make this trial possible.”
“A longer duration of postoperative complications is the main driver of prolonged hospital length of stay. With no pharmacological therapies currently available, there is a clear need for novel approaches,” said Professor Peter Pickkers, internist-intensivist at Radboud university medical center and Coordinating Principal Investigator of the EasyBoost trial.
“Currently there is no specific therapy to improve patient recovery after major surgery, while reducing hospital length of stay is a very important patient-centred outcome,” said Professor Marlies Ostermann, President of the European Society of Intensive Care Medicine (ESICM) and one of the participating investigators.
About EA-230
EA-230 is a synthetic tetrapeptide (AQGV; alanine-glutamine-glycine-valine) derived from the human pregnancy hormone hCG and developed by EBI. EA-230 is administered as a single four-hour intravenous infusion during surgery, which fits seamlessly into existing surgical workflows, and is being investigated for its potential to support vascular integrity and haemodynamic stability during the physiological stress associated with major surgery, with the aim of reducing the duration of postoperative complications and improving recovery. EA-230 has been studied in Phase I trials in healthy volunteers, a Phase IIa human endotoxaemia study and a Phase II trial in 180 cardiac surgery patients. It is produced by chemical synthesis. EA-230 is an investigational product and has not been approved by any regulatory authority.
About EBI
Exponential Biotherapies, Inc. (EBI), is a privately held, clinical-stage biopharmaceutical company incorporated in Delaware, with offices in New York, New York. EBI conducts its research and development activities through its subsidiaries and group companies in the Netherlands, based in The Hague, including EBI NL, the group company that sponsors the EA-230 clinical program. EBI is pioneering potential first-in-class therapeutic peptides, derived from a protective mechanism of human pregnancy, for patients in acute, perioperative and critical care. Its lead product candidate, EA-230, is in Phase III development to improve recovery after cardiac surgery. EBI works with specialised clinical, manufacturing and academic partners and is supported by a Scientific Advisory Board of leading international experts.
About CR2O
CR2O is a Netherlands-based, full-service Contract Research Organisation supporting biotechnology and pharmaceutical companies in the planning and execution of clinical development programmes. CR2O is supporting the international execution of the EasyBoost Phase III trial.
Further information about EBI, EA-230 and the EasyBoost Phase III trial is available at www.expobio.com and ClinicalTrials.gov.
Notes to editors
The Phase II trial (NCT03145220) was conducted at Radboud university medical center. Its primary endpoint was safety; efficacy endpoints, including hospital length of stay, were exploratory. Reference: van Groenendael R, et al. Critical Care Medicine 2021;49:790-803.
Contact
EBI Business Development: Otto Paul Brand
Email: Enquiries@expobio.com
-
DXC 携手 Cisco,通过 DXC OASIS 将 AI 驱动的网络洞察转化为实际行动* DXC 将 Cisco 的 AI 网络智能能力与 DXC OASIS 相结合,通过企业级编排与人工监督,加快事件处置。 * 双方合作将首先聚焦 Cisco Meraki 环境下的办公场所 Wi-Fi2026-11-19
-
Cognizant® Patient Hub Operations 正式推出:AI 赋能的患者治疗支持解决方案,旨在缩短从处方开具到接受治疗的时间Cognizant Patient Hub Operations 基于 NVIDIA 加速计算构建,旨在减少行政流程造成的治疗延误,让患者支持项目能够服务更多患者,而文书工作量无需随之等比例增加。2026-11-19
-
欧莱雅中国获颁全球外资研发中心证书 彰显“全球芯、中国心、未来兴”研发理念上海2026年11月19日 美通社 -- 第四十三批跨国公司地区总部和研发中心颁证仪式昨日举行,欧莱雅中国获颁全球外资研发中心证书。此前,欧莱雅旗下专注于体外重建人体皮2026-11-19
-
华纳音乐集团首席执行官 Robert Kyncl 将在 CES 2027 上探讨音乐的未来作为首位发表 CES 官方主题演讲的音乐公司掌门人,Kyncl 将前瞻音乐创作与互动的全新阶段 弗吉尼亚州阿灵顿2026年11月19日 美通社 -- 美国消费技术协会(CTA)® 《ht2026-11-19
-
品牌一致性背后的运营挑战,Monotype(蒙纳字库)最新研究带来哪些发现?Monotype 研究显示,62% 的受访者将字体缺失或不匹配列为工作流中的三大痛点之一,这凸显了维系品牌一致性所面临的运营难题。 马萨诸塞州沃本2026年11月19日 美通社2026-11-19
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
锚定健康中国新征程!第一届医药信息传播论坛将于广州启幕
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
